Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Recruiting · NCT04724941 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital Schleswig-Holstein
View the official record on ClinicalTrials.gov →Interventions studied
No intervention
What this trial is about
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Who can take part
Age range
50 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age between 50 and 99
Exclusion criteria
- Presence of clinical PD at the time of study inclusion
- Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
- other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
- in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Where it is running
1 location listed.
- Department for Neurology, University of Kiel - Kiel, Germany